MedTrace Logo

Pharmacokinetic Study of DA-020

NCT07402330 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-13

No results posted yet for this study

Summary

Pharmacokinetic Study of DA-020

Conditions

  • Chemotherapy Induced Alopecia
  • Chemotherapy Side Effects

Interventions

DRUG

DA-020 (0.1%)

DA-020 (0.1%)

DRUG

DA-020 (0.2%)

DA-020 (0.2%)

DRUG

DA-020 (0.5%)

DA-020 (0.5%)

Sponsors & Collaborators

  • Daniel Alain, Inc.

    collaborator INDUSTRY

  • Follea International Limited

    collaborator INDUSTRY

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Andy Goren, MD · University of Rome G. Marconi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-10-19
Completion
2026-11-30

Countries

  • Brazil
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07402330 on ClinicalTrials.gov